Which Pharma Company Employees Must Complete GVP Training?

Introduction

Pharmacovigilance is the practice of monitoring the safety of medicines after they have been licensed for use and is crucial for protecting patient well-being. To safeguard patients and comply with regulatory requirements, pharma companies must follow the pharmacovigilance regulations for approved medicines laid out in the Good Pharmacovigilance Practice (GVP) guidelines. Part of these requirements includes an adequate level of pharmacovigilance training for personnel.

This post will explain which pharma company employees need to complete pharmacovigilance courses and how to meet your GVP obligations through accredited GVP training.

What is GVP, and how does it relate to pharmacovigilance?  

GVP is one of several Good Practice (GxP) guidelines that apply to the biopharmaceutical companies. Its purpose is to ensure medicines are safe and effective by vigilantly monitoring the effects of approved medicines on patients, a practice known as pharmacovigilance. 

Pharma companies must meet the regulatory requirements within each country they operate in and understand how they have been translated into law by the local regulatory body, such as the FDA in the United States or the EMA in the European Union. 

GVP expectations vary geographically, with the EMA holding a much broader oversight scope than the FDA, including post-marketing authorization pharmacovigilance activities, for example, whereas the FDA only regulates surveillance post-marketing approval. 

GVP specifically provides a framework for: 

• Identifying and describing safety signals from case reports and case series 

• Investigating, interpreting, and assessing safety signals (such as how to grade an adverse event on a severity scale) and whether to assign it as a likely reaction to treatment 

• Developing a pharmacovigilance plan 

The consequences of noncompliance can be severe and include fines, product recalls, and damage to a company’s reputation. Most importantly, patient safety can be jeopardized, as adverse effects may go unrecognized if a company does not rigorously uphold GVP standards. 

Who needs to take pharmacovigilance courses, such as GVP training, in a pharma company?

Most pharma companies provide documented GVP training to a wide range of personnel to comply with the compulsory requirements and nonbinding recommendations of regulatory bodies. 

Mandatory training is required for all staff directly involved in pharmacovigilance activities, such as pharmacovigilance case handling, reporting drug safety updates, managing literature on pharmacovigilance activities, or managing safety concerns through pharmacovigilance steering committees. 

However, the extent to which other personnel within pharma companies receive pharmacovigilance training is open to interpretation. Nonbinding recommendations from the EMA suggest that “adequate” pharmacovigilance training be given to staff whose activities may have an indirect impact on pharmacovigilance. To avoid falling foul of expectations, ever-cautious pharma companies often provide GVP training to employees involved in: 

• Clinical Development, particularly clinical trial personnel 

• Medical Affairs, particularly those involved in non-interventional studies and front-line personnel such as Medical Sciences Liaisons and Medical Information Agents 

• Commercial and Marketing, particularly Sales Reps and other front-line staff 

Regulatory Affairs and Legal teams, as well as staff involved in audits many organizations opt to stick with the same rigorous standards of GLP-compliant studies as a matter of course. 

What is considered adequate pharmacovigilance or GVP training?  

The term adequate is open to interpretation, and many pharma companies take a conservative approach, preferring caution over suffering consequences, when it comes to pharmacovigilance training. 

The pharmacovigilance team should receive documented, periodic training related to GVP. This includes requirements and processes for documentation and record keeping, such as standard operating procedures. The training should include a foundation in pharmacovigilance practice (if appropriate to their experience level), plus in-depth training related to their specific work activities. 

For other pharma personnel with indirect involvement in pharmacovigilance activities, courses that provide an introduction to GVP or a global awareness of pharmacovigilance can provide a good starting point. 

How GxP Training Supports Your GVP Training Compliance

For both pharmacovigilance teams and personnel involved in front-line activities in Clinical Development, Commercial and Medical Affairs engagements, we at GxP Training recommend two certified courses from our catalog, which are fully aligned with auditors’ expectations: 

Introduction to Good Pharmacovigilance Practice: Gain a solid foundation in GVP principles and how they follow marketing approval in the US or marketing authorization in the EU. This course introduces key concepts of pharmacovigilance requirements, including how adverse effects are detected, recorded, assessed, understood, reported, and prevented. 

Global Pharmacovigilance Awareness: Learn the origin, scope, and purpose of pharmacovigilance; understand and compare pharmacovigilance systems and case processing; and discover how to achieve global pharmacovigilance awareness. 

All our courses are built to deliver trusted certification, with the following key benefits: 

• Self-paced e-learning modules that are available 24/7 for 12 months 

• Video-led modules followed by an exam—complete with a certified assessment to validate your knowledge 

• A unique, traceable certificate that is fully compliant and audit-ready 

• Your certificate instantly shared on LinkedIn via a secure, verifiable link 

• Enterprise features, such as compliance reporting, certificate exports, user management, and progress tracking, that teams can unlock 

Start your GVP training today, enroll your team, and get certified now!